Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Arthritis Research & Therapy

Figure 4

From: Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial

Figure 4

Patients (%) achieving minimum clinically important differences in fatigue (a), physical function (b), pain (c), and disease activity (d) over 52 weeks (ITT population, LOCF). *P < 0.001 for CZP vs PBO by repeated measures logistic regression. CZP = certolizumab pegol; FAS = fatigue assessment scale; HAQ-DI = health assessment questionnaire - disability index; ITT = intent to treat; LOCF = last observation carried forward; MCID = minimal clinically important difference; MTX = methotrexate; PBO = placebo; PtGA = patient's global assessment of disease activity; VAS = visual analog scale.

Back to article page